Chirag Dilip Jhaveri MD

Address:

Retina Consultants of Austin
3705 Medical Parkway, Ste 410
Austin, TX 78705

Retina Research Center
3705 Medical Parkway, Ste 420
Austin, TX 78705

Education

Vitreoretinal Fellowship: Northwestern University Feinberg School of Medicine
July 2010 – June 2012
Mentors: Lee M. Jampol, MD; Alice Lyon, MD; Manjot Gill, MD; Rukhsana Mirza, MD; Robert Schroeder, MD

Ophthalmology Residency: Louisiana State University/Ochsner – New Orleans, Louisiana
July 2007 – June 2010
Chief Resident – July 2009 – June 2010

Internship: Emory University School of Medicine - Atlanta, Georgia
July 2006 – June 2007
Class Representative

MD Baylor College of Medicine - Houston, Texas
August 2002 – May 2006

B.A. University of Texas at Austin - August 1998 – May 2002
College of Liberal Arts – Plan II Honors Degree
Graduated with High Honors

Foreign Languages

Conversational Spanish; Gujarati; Hindi

Work Experience

Retina Consultants of Austin - September 2012 – present
- Physician

Retina Research Center – September 2012 – present
- Investigator

Diabetic Retinopathy Clinical Research Network – January 2016 – January 2019
- Vice-Chair

LSU/Ochsner – Chief Resident – July 2009 - June 2010
- Involved in preparing site readiness for ACGME visit.
- Planning and organizing wet labs and other educational sessions for residents
- Administrative tasks of managing schedules and vacations for a 24 resident program

Baylor College of Medicine – Houston, TX. Jan 2004 – April 2004
Teaching Assistant –Preclinical Elective Courses
- Facilitator of weekly group discussions
- Aided and evaluated students in elective coursework

UT School of Public Health - Austin, Texas Feb. 2001 – May 2002
Intern/Project Assistant

- Assisted Dr. Alfred McAlister on Tobacco Settlement Project
- Worked with Dr. Alfred McAlister on Peace Project and developed high school curriculums that stressed non-violence
- Helped in teaching sessions about non-violence at local high schools

Texas Senate Finance Committee – Austin, Texas Feb. 2001 – May 2001
Legislative Intern

- Performed research for Bill Hearings and Finance Committee related reports
- Set up Committee member's Bill books for Finance Committee Bill Hearings
- Gained valuable hands-on experience and understanding of legislative processes at the state level

Appointments

Vice-Chair DRCR.net January 2016-2018
Executive Committee – DRCR
Operations Group Committee – DRCR

Protocol Chair – DRCR Protocol AC

Clinical Assistant Professor of Ophthalmology, Dell Medical School, June 2016-present
Diversity and Inclusion Task Force, Dell Medical School. October 2016-present

Clinical Assistant Professor of Ophthalmology, Texas A&M University College of Medicine, 2014-present

Publications

Bressler, Neil M. MD; Beaulieu, Wesley T. PhD; Bressler, Susan B. MD; Glassman, Adam R. MS; Melia, B. Michele ScM; Jampol, Lee M. MD; Jhaveri, Chirag D. MD; Salehi-Had, Hani MD; Velez, Gisela MD, MPH; Sun, Jennifer K. MD **ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY.** RETINA: September 17, 2019

Sahni, Jayashree; Patel, Sunil S; Dugel, Pravin U; Khanani, Arshad M.; Jhaveri, Chirag D.; Wykoff, Charles C.; Hershberger, Vrinda S.; Pauly-Evers, Meike; Sadhikhov, Shamil; Szczesny, Piotr; Schwab, Dietmar; Nogoceke, Everson; Osborne, Aaron; Weikert, Robert; Fauser, Sascha. **Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema BOULEVARD Phase 2 Randomized Trial** Manuscript no. 2018-2851.

Baker CW, Glassman AR, Beaulie WT, Antoszyk, AN, Browning DJ, Chalam KV, Grover S, Jampol LM, Jhaveri CD, Melia M, Stockdale CR, Martin DF, Sun JK. **Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual AcuityA Randomized Clinical Trial**. JAMA. 2019; doi: 10.1001/jama.2019.5790

Papangkorn K, Truett KR, Vitale AT, Jhaveri C, Scales DK, Foster S, Montieth A, Higuchi JW, Brar B, Higuchi WI. **Novel Dexamethasone Sodium Phosphate Treatment (DSP-Visulex) for Noninfectious Anterior Uveitis: Phase I/II, Double-Masked, Active Controlled, Randomized Study.** Current Eye Research, November 2018, 1460-2202. https://doi.org/10.1080/02713683.2018.1540707

Eustis HS, Janot A, Jhaveri C**. Development of Monofixation Syndrome After Extraction of Dense Cataracts.** Journal of Pediatric Ophthalmology Strabismus. 2017.

Chexal S, Gunderson I, BS, Berger BB, Jhaveri C. **A Novel Compound for Treatment of Wet AMD Retina Today**, May/June 2016 72-78.

Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network. **Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.** *Ophthalmology*. 2016 Jun;123(6):1351-9. doi: 10.1016/j.ophtha.2016.02.022.

Aiello LP, Ayala AR, Antoszyk AN, Arnold-Bush B, Baker C, Bressler NM, Elman MJ, Glassman AR, Jampol LM, Melia M, Nielsen J, Wolpert HA; Diabetic Retinopathy Clinical Research Network. **Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control: A Randomized Clinical Trial.** *JAMA Ophthalmol. 2015 Aug;133(8):888-96. doi: 10.1001/jamaophthalmol.2015.1312*

Bressler SB, Almukhtar T, Bhorade A, Bressler NM, Glassman AR, Huang SS, Jampol LM, Kim JE, Melia M; Diabetic Retinopathy Clinical Research Network Investigators. **Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.** *JAMA Ophthalmol. 2015 May;133(5):589-97. doi: 10.1001/jamaophthalmol.2015.186*

Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. **Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.** *N Engl J Med. 2015 Mar 26;372(13):1193-203. doi: 10.1056/NEJMoa1414264. Epub 2015 Feb 18*

Danylkova N, Gupta N, Jhaveri CD, Gill MK. **Suprachoroidal silicone oil migration following retinal detachment repair.** *Ophthalmic Surg Lasers Imaging Retina. 2013 May-Jun;44(3):284-6. doi: 10.3928/23258160-20130503-14*

Jhaveri CD, Jampol LM, Van Gelder RN, Cunningham ET Jr. **Diagnostic and therapeutic challenges.** *Retina. 2012 May;32(5):1028-32. doi: 10.1097/IAE.0b013e3182437e54.*

Scientific Posters

The Effect of Brolucizumab Applied by Microvolume Injection or Infusion in Patients With Neovascular Age-Related Macular Degeneration. Association for Research in Vision and Ophthalmology Annual Meeting, Seattle, WA May 2016.

Presentations

Positive Diabetic Retinopathy Outcomes with Emixustat in a Pilot Study, Association for Research in Vision and Ophthalmology Annual Meeting, Vancouver, Canada May 2019

DRCR Symposium Association for Research in Vision and Ophthalmology Annual Meeting, Vancouver Canda, May 2019

Fluctuations of Central retinal thickness and visual correlations in Hawk and Harrier Trial.
ASRS Annual Meeting, Chicago, IL. July 2019

Research Experience

Clinical Research

Sub-Investigator: A Phase 1, Multicenter, Open-Label, Single-Dose and Multiple-Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravitreal Injections of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration – (NGM Biopharmaceuticals Inc. NGM621)

Sub-Investigator: A Multi-Center, Non-randomized, Open-label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7200220 in Monotherapy and in Combination with ranibizumab Following Intravitreal Administration in Patients with Diabetic Macular Edema - (Roche BP40899 Dovetail)

Sub-Investigator: A Genetic Screening and Registry Study to Evaluate Long-term Clinical Outcomes and Disease Progression in Subjects with Non-Central Geographic Atrophy (GA) who are Carriers of High-Risk Genetic Complement Variants Associated with Dry Age-related Macular Degeneration (AMD) (Gemini GEM-NH-001)

Sub-Investigator: A Prospective Natural History Study to Evaluate Clinical Characteristics and Disease Progression in Subjects with Non-Central Geographic Atrophy (GA) who are Carriers of High-Risk Genetic Variants of Complement Factor H - (Gemini GEM-NH-002)

Sub-Investigator: A Phase 1/1b Open-label, Multi-Center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects with Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retina Vein Occlusion (RVO) - (Kodiak KSI-CL-101)

Principal Investigator: A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) – (Apellis APL2-303)

Principal Investigator: A Multicenter, Randomized, Double-Masked, Phase 3a study to Assess Safety and Efficacy of brolucizumab 6mg q4 weeks Compared to Aflibercept 2mg q4weeks in Patients with Neovascular Age-Related Macular Degeneration with Persistent Retina Fluid (MERLIN) -(Novartis Merlin)

Sub-Investigator: A Multi-Center, Non-Randomized, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200394 Following Intravitreal Administration in Patients with Neovascular Age-Related Macular Degeneration -(Roche BP40923)

Sub-Investigator: A Phase 2, Randomized, Placebo Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-L_{RX}, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) – (Ionis 696844-CS5)

Sub-Investigator: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration (Lucerne) – **(**Genentech GR40844 Lucerne)

Sub-Investigator: A Randomized, Active-Controlled, Patient and Investigator-Masked, Multiple Dose Proof-of-Concept Study of Intravitreal LKA651 in Patients with Diabetic Macular Edema - (Novartis LKA651x2202)

Sub-Investigator; A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO) – (Genentech GR40973)

Sub-Investigator: Long-term Effects of Semaglutide on Diabetic Retinopathy in Subjects with Type 2 Diabetes (FOCUS) (Novo Nordisk Focus)

Sub-Investigator: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sucutaneous Injections of Elamipretide in Subjects with Age-Related Macular Degeneration with Geographic Atrophy (Stealth SPIAM-202)

Principal Investigator: Randomized Clinical Trial Assessing the Effects of Pneumatic Vitreolysis on Vtireomacular Traction –(DRCR AG)

Principal Investigator: Single-Arm Study Assessing the Effects of Pneumatic Vitreolysis on Macula Hole - (DRCR AH)

Sub-Investigator: A Randomized, Double-Masked, Uncontrolled, Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Naïve Participants with Neovascular Age-Related Macular Degeneration (AMD)- **(**Panoptica PAN-01-102)

Principal Investigator: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration – (Genentech GR40549 Portal)

Principal Investigator: A Phase III, Multicenter, Randomized, Visual Assessor-Masked Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration - (Genentech GR40548 Archway)

Principal Investigator: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema – (Genentech GR40349 Yosemite)

Principal Investigator: A Two-Year, Three-Arm, Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema - (Novartis CRTH258B2301 Kestrel)

Sub-Investigator: A Randomized, Masked, Controlled, Trial to Study the Safety and Efficacy of Suprachoridal CLS-TA in Combination with an Intravitreal Anti-VEGF Agent in Subjects with Retinal Vein Occlusion – (Clearside CLS1003-302 TOPAZ)

Sub-Investigator: A Phase 1, Open-label, Multicenter, Dose Escalation study to Evaluate the safety of a Single Intravitreal injection of THR-149 for Treatment of Diabetic Macular Edema (DME) – (Thrombogenics THR-149-001)

Sub-Investigator: A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients with Choroidal Neovascularization Secondary to Age-related Macular Degeneration (Iconic IT-004)

Sub- Investigator: A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Wet Age-related Macular Degeneration (Santen 36-002 Avante)

Sub-Investigator: A Dose-ranging Study of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age Related Macular Degeneration (wet AMD) (Opthea OPT-302-1002)

Sub-Investigator: A Randomized Sham-Controlled Double-Masked Phase 2a study of the Efficacy, Safety and Tolerability of the Intravitreal Plasma Kalikrein Inhibitor, KVD001, in Subjects with Center-Involving Diabetic Macular Edema (ciDME) who have had prior Anti-VEGF treatment (Kalvista KVD001-201)

Principal Investigator: PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate versus Placebo (DRCR Protocol AD)

Principal Investigator Randomized Trial of Intravitreous Aflibercept versus Intravitreous Bevacizumab +
Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema (DRCR Protocol AC)

Principal Investigator: Intravitreous Anti-VEGF vs. Prompt Vitrectomy for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy (DRCR Protocol AB)

Sub-Investigator: A Phase I/II Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects with Neovascular Age-Related Macular Degeneration (Graybug GBV-102-001)

Principal Investigator: A Randomized, Double-Masked, Placebo-Controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered
BI 1467335 for 12 weeks with a 12 week follow up period in patients with Non-proliferative diabetic retinopathy without center-involved diabetic macular edema (Boehringer-Ingelheim 1386.12 Robin)

Sub-Investigator: Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg twice daily for 12 months in Patients with Moderate to Severe Non-Proliferative Diabetic Retinopathy (Aerpio AKB-9779-CI-5001 Time-2b)

Sub-Investigator: A Phase 3 Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2 (Neurotech NTMT-03-B Renexus)

Principal Investigator: A Natural History Observation and Registry Study of Macular Telangiectasia Type 2 (The Lowy Medical Research Institute, Mactel Project)

Principal Investigator: A Phase IIa Trial Of TLC399 (ProDex) in Subjects with Macular Edema due Retina Vein Occlusion (RVO): A Double-masked, Randomized Trial to Evaluate Efficacy and Tolerability (Taiwanese Liposome Company TLC399 ProDex)

Sub-Investigator: A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy **(**Regeneron Pharmaceuticals, Inc. VGFTe-OD-1411 Panorama)

Sub-Investigator: A Multicenter, Open-label, Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration who have Completed a Roche-Sponsored Study (Genentech GX30191 Omaspect)

Sub-Investigator: Simultaneous Blockade of Angiopoietin-2 and VEGF-A with the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration (F. Hoffman-La Roche Ltd., CR29521 Stairway)

Sub-Investigator: A Phase II, Multicenter, Randomized, Active-Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration (F. Hoffman-La Roche Ltd, GX28228 Ladder)

Principal Investigator: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Pilot Study to Evaluate Effects of Emixustat Hydrochloride on Aqueous Humor Biomarkers Associated with Proliferative Diabetic Retinopathy (Acucela Inc., 4439-203)

Sub-Investigator: A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration (Santen Inc., PAVE study)

Principal Investigator: A Randomized, Double Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration (Regeneron Pharmaceutical, Inc, R910-3-AMD-1517 ONYX)

Principal Investigator: A Multiple-Center, Multiple-Does, Randomized, Active Comparator-Controlled, Double-Masked, Parallel-Group, 28-Week Study to Investigate the Safety, Tolerability, Pharmaokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Diabetic Macular Edema (Genentech BP30099 Boulevard)

Principal Investigator: Intravitreous Anti-VEGF Treatment for Prevention of Vision Threating Diabetic Retinopathy in Eyes at High Risk (DRCR Protocol W)

Sub-Investigator: Genes in Diabetic Retinopathy Project (DRCR Genetics)

Sub-Investigator: Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy (DRCR Protocol S)

Sub-Investigator: A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (Genentech BP29647 Avenue)

Sub-Investigator: A Phase 2 Multicenter, Randomized, Controlled, Double-Masked Clinical Trial Designed to Evaluate the Safety and Exploratory efficacy of Luminate® (ALG-1001) as Compared to Avastin® in the Treatment of Diabetic Macular Edema (Allegro Ophthalmics, LLC, DME 202B)

Sub-Investigator: An open-label single ascending dose and randomized double-masked, ranibizumab controlled, safety, tolerability, and efficacy study of intravitreal LMG324 in subjects with neovascular age-related macular degeneration (Alcon Research, LTD, LMG324-2201)

Sub-Investigator: A randomized, multi-center, single masked, sham controlled, proof-of-concept study of intravitreal CLG561 as a monotherapy and in combination with LFG316 in subjects with geographic atrophy (Alcon Research, LTD, CLG561-2201)

Sub-Investigator: A Phase 4 Safety Study of IOP Signals Inpatients Treated with Iluvien® (Fluocinolone Acetonide Intravitreal Implant) 0.19 MG (Alimera Sciences, Inc., M-01-15-004)

Sub-Investigator: Prospective, Multicenter Post-Approval Study (PAS) of Visioncare's Implantable Miniature Telescope (By Dr. Isaac Lipshitz) in Patients with Bilateral Severe to Profound Central Vision Impairment

Associated with End-Stage Age-Related Macular Degeneration (VisionCare Ophthalmic Technologies, IMT-PAS-01)

Sub-Investigator: Clinical Study Protocol Phase 1 Dose Escalation and Expansion Study of DS-7080a in Subjects with Neovascular Age-Related Macular Degeneration (Daiichi Sankyo Pharma Development, DS7080-A-U101)

Principal Investigator: A Randomized, Double Masked, Three Dose Safety and Pharmacokinetic Study of RTH258 Following Intravitreal (IVT) Injection in Subjects with Neovascular Age-Related Macular Degeneration (Alcon Research, Ltd., RTH258-E003)

Principal Investigator: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients with Geographic Atrophy (GA) - FILLY – (Apellis Pharmaceuticals, Inc., POT-CP121614)

Principal Investigator: A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-Inferiority Study of X-82 plus *prn* Eylea® Compared to *prn* Eylea® Monotherapy in Neovascular AMD (Tyrogenex, Inc., X82-OPH-201)

Sub-Investigator: A Phase II Proof-of-Concept Study of the Safety and Efficacy of HuCNS-SC Subretinal Transplantation in Subjects with Geographic Atrophy of Age-Related Macular Degeneration (StemCells, Inc., CL-AMD-201)

Principal Investigator: Prospective, observational longitudinal study addressing Peripheral Diabetic Retinopathy (DR) Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time (DRCR AA)

Sub-Investigator: A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in Subjects with Neovascular
Age-Related Macular Degeneration (Alcon Research Ltd. RTH258-C001)

Sub-Investigator: A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients with Choroidal Neovascularization Secondary to Age-related Macular Degeneration (Iconic Therapeutics IT-002)

Sub-Investigator: A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema (Astellas Pharma Europe B.V. VIDI)

Principal Investigator: A randomized, parallel group, double-masked, active-controlled Phase ½ clinical Trial to evaluate the efficacy and safety of dexamethasone sodium phosphate Visulex system for the treatment of non-infectious anterior uveitis (Aciont, Inc. DSPV-201)

Sub-Investigator**:** A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patient with Geographic Atrophy Secondary to Age-Related Macular Degeneration (Genentech GX29176 Chroma)

Sub-Investigator: Study of Comparative Treatments for Retinal Vein Occlusion 2 [SCORE2]: A Multicenter, Prospective, Randomized Non-Inferiority Trial of Eyes with Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 weeks with Intravitreal Aflibricept Every 4 weeks (SCORE2)

Sub-Investigator: A Randomized, Double Masked, Placebo Controlled Study Evaluating ORACEA® in Subjects with Geographic Atrophy Secondary to Non-Exudative
Age-Related Macular Degeneration (University of Virginia Department of Ophthalmology TOGA)

Sub-Investigator: A Phase 1 Open-Label, Multi-Center Trial with Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Neovascular Age-Related Macular Degeneration (AMD) (Panoptica PAN-90806)

Sub-Investigator: A Phase 2, Randomized, Active- Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects with Diabetic Macular Edema (Aerpio AKB-9778):

Principal Investigator: Ocriplasmin Research to Better Inform Treatment (Thrombogenics TG-MV-018 ORBIT**)**

Principal Investigator: Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good
Visual Acuity (DRCR Protocol V)

Sub-Investigator: Short-term Evaluation of Combination Corticosteroid+Anti-VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy in Pseudophakic Eyes (DRCR Protocol U)

Sub-Investigator: A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X 0.024% (Latanoprostene Bunod) Ophthalmic Solution with Timolol Maleate Ophthalmic Solution 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension (Bausch & Lomb APOLLO)

Sub-Investigator: A Phase 3, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDG-F Pegylated Aptamer) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration (Ophthotech Corp. OPH1003)

Sub-Investigator: A prospective, Two Cohort, Single-Masked, Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects with Exudative Age-Related Macular Degeneration (Alcon C-13-001 ESBA1008)

Sub-Investigator: An Open-Label, Non-randomized, Single-Arm, Roll-Over Study to Continue Dosing of Gevokizumab in Non-Infectious Intermediate, Posterior, or Pan- Uveitis Patients Who Each Successfully Completed either the X052130 or the X052131Study (XOMA X052132)

Sub-Investigator: A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina in Adults Patients with Diabetic Macular Edema (Ampio Pharmaceuticals, Optina Danazol Oral Capsule Clinical Study AP-05-002)

Sub-Investigator: A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel Group, Multi Center, Study to Compare the Efficacy and Safety of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) with that of Ranibizumab in Adult Subjects with Diabetic Macular Edema (Pfizer PF-04634817)

Sub-Investigator: A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema (DRCR Protocol T)

Sub-Investigator: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan-Uveitis (XOMA X052130)

Sub-Investigator: A Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled with Systemic Treatment (XOMA X052131)

Sub-Investigator: A Randomized, Multi-center, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema With Involvement of the FoveAL Center (Juvenile Diabetes Research Foundation International iDEAL Study)

Sub-Investigator: An Open-label Dose Escalation Study of PF-04523655 (Stratum I) Combined With a Prespective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating the Efficacy and Safety of PF-04523655 Alone and in Combination with Ranibizumab Versus Ranibizumab Alone in Diabetic Macular Edema (Quark, MATISSE Study)

Sub-Investigator: Effect of Diabetes Education during Retinal Ophthalmology Visits on Diabetes Control (DRCR M)